NPK PHARMASOFT LLC announces the inclusion of a new indication – attention deficit hyperactivity disorder in children (aged 6 years and over), including hyperactivity, attention deficit, and impulsivity – in the instructions for medical use of the medicinal product Mexidol® film-coated tablets, 125 mg1,2.
In children with hyperactivity and attention deficit, Mexidol® helps to increase concentration and the ability to focus, increase perseverance, reduce signs of hyperactivity and decrease impulsivity, which helps to improve the learning and social adaptation of children2.
1Letter from the Department for Regulation of Circulation of Medicines and Medical Devices of the Ministry of Health of Russia dated 08.02.2023 No. 25-6-4236081/Izm/R/Izm.
2Package leaflet – information for the patient (LP-No. (000086)-(RG-RU) dated October 30, 2020) — https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=bf67bb45-298d-45a0-a03a-9bbee2b1ecbc.
